(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Party Urban areas of the World - 2EU Council president: Ukraine should receive binding guarantees
- 3Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
- 4'Seditious behavior': Trump accuses Democrats who made video reminding the military not to follow illegal orders of a crime — but is it?
- 5Instructions to Utilize the Towing Highlights of the Slam 1500 Productively.
- Survey: Canteen Cups With Great Warm Protection Impact
- German finance minister sees advantages of smartphones in schools
- Artemis II astronauts channel Apollo 8 with a striking Earthset photo
- Barry Manilow reveals lung cancer diagnosis and plans to undergo surgery: 'It's pure luck' it was 'found so early'
- Photos: Hundreds Gather at Bondi Beach After Deadly Attack
- Extreme Manual for Purchasing Your Next Truck
- Extravagance SUVs for Seniors: Solace, Innovation, and Security
- Which Countries Would Suffer Most in a Global Energy Shutdown? This Study Has Answers
- Why do people have baby teeth and adult teeth?
